As of June 11, 2026, KalVista Pharmaceuticals, Inc. was taken private. KalVista Pharmaceuticals, Inc. operates as a biopharmaceutical company that develops oral therapies for rare diseases in worldwide markets. It offers sebetralstat, a novel, oral, on-demand treatment for hereditary angioedema (HAE), and an oral Factor XIIa inhibitor program. KalVista Pharmaceuticals, Inc. was formerly known as KalVista Pharmaceuticals Ltd. and changed its name to KalVista Pharmaceuticals, Inc. in November 2016. KalVista Pharmaceuticals, Inc. is headquartered in Framingham, Massachusetts. As of June 11, 2026, KalVista Pharmaceuticals, Inc. operates as a subsidiary of Chiesi Farmaceutici S.p.A. Show more

200 Crossing Boulevard, Framingham, MA, 01702, United States

Biotechnology

Healthcare

Market Cap

1.438B

52 Wk Range

$9.83 - $27.00

Previous Close

$27.00

Open

$27.00

Volume

N/A

Day Range

$27.00 - $27.00

Enterprise Value

1.304B

Cash

285M

Avg Qtr Burn

-14.46M

Insider Ownership

1.72%

Institutional Own.

Qtr Updated

03/31/26

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
EKTERLY® (sebetralstat) Details Hereditary angioedema	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Sebetralstat (KVD900) (film coated) Details Hereditary angioedema	sNDA Submission	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
KVD824 (plasma kallikrein enzyme inhibitor) Details Hereditary angioedema , Rare diseases, Rare genetic disease	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
KVD001 (IVT) Details Diabetic macular edema, Frontotemporal dementia with C9orf72 mutation, Dementia, Diabetes	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.